Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study-Reference-Cited by-同舟云学术

Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study

Published:2023-07 Issue:4 Volume:22 Page:730-737
ISSN:1569-1993
Container-title:Journal of Cystic Fibrosis
language:en
Short-container-title:Journal of Cystic Fibrosis

Author:

Bower Julie K.,Volkova Nataliya,Ahluwalia Neil,Sahota Gurvaneet,Xuan Fengjuan,Chin Anna,Weinstock Tanya G.,Ostrenga Josh,Elbert Alexander

Funder

Vertex Pharmaceuticals Incorporated

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Reference23 articles.

1. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA;Riordan;Science,1989

2. Cystic fibrosis;O'Sullivan;Lancet,2009

3. The future of cystic fibrosis care: a global perspective;Bell;Lancet Respir Med,2020

4. Cystic fibrosis;Elborn;Lancet,2016

5. CFTR function and prospects for therapy;Riordan;Annu Rev Biochem,2008

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor;The Journal of Pediatrics;2024-11

2. A case of severe pulmonary exacerbation in a young patient with cystic fibrosis in the era of CFTR modulators;International Journal of Infectious Diseases;2024-10

3. Unveiling the Psychosocial Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Cystic Fibrosis Patients;2024-09-04

4. Dried Blood Spot Method Development and Clinical Validation for the Analysis of Elexacaftor, Elexacaftor-M23, Tezacaftor, Tezacaftor-M1, Ivacaftor, Ivacaftor Carboxylate, and Hydroxymethyl Ivacaftor Using LC-MS/MS;Therapeutic Drug Monitoring;2024-08-27

5. Epidemiology of advanced cystic fibrosis lung disease in the modulator era;Current Opinion in Pulmonary Medicine;2024-08-23